- Home
- ADI vs BMY Comparison
ADI vs BMY Comparison
Compare ADI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADI
- BMY
- Stock Information
- Founded
- ADI 1965
- BMY 1887
- Country
- ADI United States
- BMY United States
- Employees
- ADI N/A
- BMY N/A
- Industry
- ADI Semiconductors
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- ADI Technology
- BMY Health Care
- Exchange
- ADI Nasdaq
- BMY Nasdaq
- Market Cap
- ADI 114.9B
- BMY 94.0B
- IPO Year
- ADI 1972
- BMY N/A
- Fundamental
- Price
- ADI $235.34
- BMY $44.77
- Analyst Decision
- ADI Buy
- BMY Hold
- Analyst Count
- ADI 22
- BMY 15
- Target Price
- ADI $270.00
- BMY $57.64
- AVG Volume (30 Days)
- ADI 2.8M
- BMY 18.1M
- Earning Date
- ADI 11-25-2025
- BMY 10-30-2025
- Dividend Yield
- ADI 1.66%
- BMY 5.57%
- EPS Growth
- ADI 18.69
- BMY N/A
- EPS
- ADI 3.93
- BMY 2.49
- Revenue
- ADI $10,386,795,000.00
- BMY $47,704,000,000.00
- Revenue This Year
- ADI $17.26
- BMY N/A
- Revenue Next Year
- ADI $13.24
- BMY N/A
- P/E Ratio
- ADI $60.54
- BMY $17.92
- Revenue Growth
- ADI 7.08
- BMY 2.57
- 52 Week Low
- ADI $158.65
- BMY $42.96
- 52 Week High
- ADI $258.13
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- ADI 39.98
- BMY 44.11
- Support Level
- ADI $233.55
- BMY $44.25
- Resistance Level
- ADI $246.20
- BMY $48.58
- Average True Range (ATR)
- ADI 5.00
- BMY 1.14
- MACD
- ADI -1.37
- BMY 0.02
- Stochastic Oscillator
- ADI 16.12
- BMY 28.85
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.